Federal Trade Commission

FTC Finalizes Consent Order in Amgen’s Acquisition of Horizon Therapeutics, Ensuring Continued Pharmaceutical Competition

The Federal Trade Commission (FTC) has recently finalized a consent order that resolves potential competition issues arising from Amgen Inc.’s acquisition of Horizon Therapeutics plc. This follows the dismissal of …

FTC Finalizes Consent Order in Amgen’s Acquisition of Horizon Therapeutics, Ensuring Continued Pharmaceutical Competition Read More
Federal Trade Commission

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics

The Federal Trade Commission (FTC) recently announced that it has moved to dismiss its case against pharmaceutical giant Sanofi following the company’s decision to terminate its proposed acquisition of an …

FTC Dismisses Case Against Sanofi After Termination of Proposed Acquisition of Pompe Disease Drug License from Maze Therapeutics Read More


Federal Trade Commission

FTC Files Amicus Brief Highlighting Anticompetitive Harm from Improperly Listed Patents in FDA’s ‘Orange Book’

The Federal Trade Commission (FTC) filed an amicus brief on November 20, 2023, addressing the anticompetitive harm resulting from improperly listed patents in the Food and Drug Administration’s (FDA) “Approved …

FTC Files Amicus Brief Highlighting Anticompetitive Harm from Improperly Listed Patents in FDA’s ‘Orange Book’ Read More